Compare TRAX & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAX | PRLB |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2026 | 2011 |
| Metric | TRAX | PRLB |
|---|---|---|
| Price | $47.69 | $66.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $75.17 | ★ $101.25 |
| AVG Volume (30 Days) | ★ 716.3K | 255.0K |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ 1.19 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.78 |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | ★ N/A | $57.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.69 | $46.07 |
| 52 Week High | $54.78 | $99.96 |
| Indicator | TRAX | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 36.07 |
| Support Level | $35.11 | $55.36 |
| Resistance Level | $48.94 | $67.26 |
| Average True Range (ATR) | 3.20 | 4.80 |
| MACD | 0.15 | -0.45 |
| Stochastic Oscillator | 39.33 | 19.40 |
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.